Teva Pharmaceuticals to Pay $54 Million to Settle Healthcare-Based FCA Claims

PilieroMazza PLLC
Contact

PilieroMazza PLLC

A qui tam False Claims Act (FCA) action brought by two whistleblowers alleging violations of the Anti-Kickback Statute (AKS) has resulted in a $54-million settlement from Teva Pharmaceuticals USA, Inc. and two subsidiaries (Teva) in the case of United States ex rel. Arnstein and Senousy v. Teva Pharmaceuticals USA, Inc. Although it was alleged that the federal government and various state and local governments suffered damages as a result of Teva’s actions, they declined to intervene in the case. Teva’s settlement highlights whistleblower incentives to file costly FCA claims against government contractors.

The whistleblowers were former Teva sales representatives. Their complaint alleged that, beginning in 2003, Teva held speaking events relating to its multiple sclerosis drug, Copaxone, and Parkinson’s disease drug, Azilect. The whistleblowers contended that doctors speaking at these events gave similar speeches to the same audience members, yet received honoraria between $1,500 and $2,700 for each speaking program they attended. According to the whistleblowers, this payment was used to induce doctors to prescribe Copaxone and Azilect. Pharmacies that filled these prescriptions then submitted claims for reimbursement to government-funded healthcare programs.

The AKS, among other things, criminalizes the payment of kickbacks to prompt someone to recommend a drug covered through a healthcare program. According to the whistleblowers, Teva’s payments of speaker fees to physicians constituted such a kickback. Congress amended the AKS in 2010 to provide for potential liability under the FCA for certain AKS-related activities that implicated fraud against the government, which made it possible to bring FCA allegations against Teva.

The FCA allows a reward of up to 30% for whistleblowers who recover funds on behalf of the government through the filing of FCA litigation in which the government does not intervene. In accordance with the settlement agreement between Teva and the plaintiffs, the plaintiffs and their attorneys will receive a relator fee of almost $14.6 million.

As this case shows, the FCA is a powerful tool that even private citizens can try to enforce without government intervention. It also exemplifies the potential financial threat whistleblowers can pose to government contractors, even without a finding of FCA liability. Simply put, if a company’s actions can be construed as intentionally misleading the government, this could result in a costly FCA claim.

Special thanks to Firm Paralegal, Emmanuel Elone, for his assistance with this post.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© PilieroMazza PLLC | Attorney Advertising

Written by:

PilieroMazza PLLC
Contact
more
less

PilieroMazza PLLC on:

Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide
- hide

This website uses cookies to improve user experience, track anonymous site usage, store authorization tokens and permit sharing on social media networks. By continuing to browse this website you accept the use of cookies. Click here to read more about how we use cookies.